Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab (MAINRITSAN3)

• ClinicalTrials.gov Identifier: NCT02433522
• Recruitment Status: Completed
• First Posted: May 5, 2015
• Last Update Posted: April 19, 2021
• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: Roche Pharma AG
• Information provided by (Responsible Party): Assistance Publique - Hôpitaux de Paris

Study Description

Brief Summary:

MAINRITSAN study compared Rituximab and azathioprine as maintenance therapy for ANCA-associated vasculitides. In this study, Rituximab (5 infusions at D1, D15, M6, M12, M18) was superior to azathioprine (2 mg/kg/day) to prevent relapses of AAV 28 months after the inclusion (Guillevin et al. NEJM 2014). Nevertheless, in the follow-up study of MAINRITSAN, up to 30% of patients experienced a relapse 38 months after the last rituximab infusion (unpublished data). Right now, no randomized controlled study has been carried in order to evaluate the best duration of the maintenance treatment with rituximab.

The investigators objective is to evaluate the efficacy of a long term rituximab treatment to prevent relapses of ANCA-associated vasculitis in patients in remission after a first phase of rituximab maintenance treatment.

The investigators will conduct a randomized placebo-controlled trial of a long term rituximab maintenance treatment (46 months) against a conventional maintenance treatment (18 months).

Condition or disease	Intervention/treatment	Phase
ANCA-associated Vasculitides	Drug: rituximab; Drug: Placebo	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 97 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial
• Actual Study Start Date: March 31, 2015
• Actual Primary Completion Date: August 16, 2018
• Actual Study Completion Date: August 16, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Rituximab; 500 mg rituximab infusion at the randomization visit and every 6 months for 18 months	Drug: rituximab; 500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
Placebo Comparator: Placebo; Placebo infusion at the randomization visit and every 6 months for 18 months	Drug: Placebo

Outcome Measures

Primary Outcome Measures :

1. Vasculitis score 2003 (BVAS 2003 ) [ Time Frame: 28 months ]
   Relapse free survival rates (BVAS > 0)

Secondary Outcome Measures :

1. Number of adverse events, [ Time Frame: 28 months ]
   adverse events including infectious effects and their severity in each arm
2. number of patients experiencing at least one adverse event in both arms [ Time Frame: 28 months ]
3. correlation of ANCA level with the clinical events [ Time Frame: 28 months ]
4. ANCA level during follow-up [ Time Frame: 28 months ]
5. correlation B-Lymphocytes CD-19 level with the clinical events [ Time Frame: 28 months ]
6. B-Lymphocytes CD-19 level during follow-up [ Time Frame: 28 months ]
7. number of B memory cells during follow-up in both arms [ Time Frame: 28 months ]
8. correlation number of B memory cells with the clinical events [ Time Frame: 28 months ]
9. Number of patients with ANCA in each arm [ Time Frame: 28 months ]
10. Time frame to death in both arms [ Time Frame: 28 months ]
11. time frame of first minor relapse [ Time Frame: 28 months ]
12. time frame of first major relapse [ Time Frame: 28 months ]
    "the reappearance of disease activity or worsening, with a Birmingham Vasculitis Activity Score >0, and involvement of one or more major organs, disease-related life-threatening events, or both"
13. Cumulated dose of corticosteroid treatment [ Time Frame: 28 months ]
14. Number and severity of damages [ Time Frame: 28 months ]
15. number of of gammaglobulins [ Time Frame: 28 months ]
16. Quality of life : SF36 (The Short Form (36) Health Survey) [ Time Frame: 28 months ]
17. functional capacities : HAQ (Health Assessment Questionnaire ) [ Time Frame: 28 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

First, patients must have been included in MAINRITSAN 2 and in addition to meeting the criteria for inclusion and non-inclusion.

MAINRITSAN 2 inclusion criteria:

• Granulomatosis with Polyangiitis Or microscopic polyangiitis complying Or kidney-limited disease With or without detectable ANCA (anti-neutrophil cytoplasmic antibodies) at the time of diagnosis or relapse, and at remission.
• Who have achieved remission using a treatment combining corticosteroids and an immunosuppressive agent, including corticosteroids, cyclophosphamide IV or oral (the use of another immunosuppressant is allowed, according to the current French guidelines, as well as plasma exchanges and/or IV immunoglobulins, or rituximab).
• Interval of 1 month between the end of the immunosuppressant treatment and the randomization time if cyclophosphamide or methotrexate were used, interval between 4 and 6 months if rituximab was used
• Age > 18 years without age limit higher when the diagnosis is confirmed.
• Informed and having signed the consent form to take part in the study.

and Patients must meet all of the following criteria:

• In complete remission (BVAS 0) at 28 months of MAINRITSAN2 study.
• Informed patient who accepted to participate in MAINRITSAN 2 and who signed the informed consent to this extension.
• Randomized on the day of the evaluation of the primary endpoint of MAINRITSAN 2 during the visit M28 (last visit of the protocol).

Exclusion Criteria:

• Eosinophilic granulomatosis with polyangiitis (EGPA)
• History of severe allergic manifestations or anaphylactic manifestations following humanized or murine monoclonal antibodies infusions
• Pregnant or breast feeding women. Contraception is required for women who could be pregnant during treatment follow up and during the year following the last infusion.
• Infection by HIV (positive serology), HCV (positive serology), or HBV (HBsAg positive or anti-HBc antibody positive with anti-HBs antibody negative)
• Uncontrolled infection at time of inclusion in the extended follow-up study.
• Other severe bacterial, viral , mycobacterial or fungal infection(s), occurring within the last 3 months before of randomization. A severe infection is defined by the hospitalization, a life or organ threatening.
• Severe chronic obstructive bronchopathy (FEV < 50% or dyspnea stage III).
• Cardiac failure, stage IV according to the NYHA classification.
• Recent history of coronary artery disease (<1 month).
• Ongoing malignancy or hematologic disease within 5 years before inclusion.
• Patient with severe immunodepression characterized by clinical manifestations.
• Participation to another concomitant therapeutic study (except observational studies or studies without therapeutic intervention).
• Psychiatric disease that may interfere with the study.
• Non affiliation to a health insurance.
• Uncontrolled severe cardiac disease.

Contacts and Locations

Locations

France

Hopital cochin

Paris, France, 75014

Sponsors and Collaborators

Assistance Publique - Hôpitaux de Paris

Roche Pharma AG

Investigators

• Study Chair: Loic GUILLEVIN, MD-PhD; Assistance Publique - Hôpitaux de Paris

More Information

Publications:

Pagnoux C, Guillevin L; French Vasculitis Study Group; MAINRITSAN investigators. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. N Engl J Med. 2015 Jan 22;372(4):386-7. doi: 10.1056/NEJMc1414728. No abstract available.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Charles P, Perrodeau E, Samson M, Bonnotte B, Neel A, Agard C, Huart A, Karras A, Lifermann F, Godmer P, Cohen P, Hanrotel-Saliou C, Martin-Silva N, Pugnet G, Maurier F, Sibilia J, Carron PL, Gobert P, Meaux-Ruault N, Le Gallou T, Vinzio S, Viallard JF, Hachulla E, Vinter C, Puechal X, Terrier B, Ravaud P, Mouthon L, Guillevin L; French Vasculitis Study Group. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med. 2020 Aug 4;173(3):179-187. doi: 10.7326/M19-3827. Epub 2020 Jun 2.

• Responsible Party: Assistance Publique - Hôpitaux de Paris
• ClinicalTrials.gov Identifier: NCT02433522
• Other Study ID Numbers: P110146 extended; 2012-001963-66 ( EudraCT Number )
• First Posted: May 5, 2015
• Last Update Posted: April 19, 2021
• Last Verified: April 2021

Keywords provided by Assistance Publique - Hôpitaux de Paris:

ANCA-associated vasculitides; Maintenance treatment; Rituximab; Granulomatosis with polyangiitis; Microscopic polyangiitis

Additional relevant MeSH terms:

Vasculitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Vascular Diseases; Cardiovascular Diseases; Systemic Vasculitis; Skin Diseases, Vascular; Skin Diseases; Autoimmune Diseases; Immune System Diseases; Rituximab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents